These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

920 related items for PubMed ID: 28716027

  • 1. Cytomegalovirus viraemia and mortality in renal transplant recipients in the era of antiviral prophylaxis. Lessons from the western Australian experience.
    Selvey LA, Lim WH, Boan P, Swaminathan R, Slimings C, Harrison AE, Chakera A.
    BMC Infect Dis; 2017 Jul 17; 17(1):501. PubMed ID: 28716027
    [Abstract] [Full Text] [Related]

  • 2. CMV mismatch does not affect patient and graft survival in UK renal transplant recipients.
    Johnson RJ, Clatworthy MR, Birch R, Hammad A, Bradley JA.
    Transplantation; 2009 Jul 15; 88(1):77-82. PubMed ID: 19584684
    [Abstract] [Full Text] [Related]

  • 3. High risk of cytomegalovirus infection following solid organ transplantation despite prophylactic therapy.
    Harvala H, Stewart C, Muller K, Burns S, Marson L, MacGilchrist A, Johannessen I.
    J Med Virol; 2013 May 15; 85(5):893-8. PubMed ID: 23508914
    [Abstract] [Full Text] [Related]

  • 4. Effect of cytomegalovirus viremia on subclinical rejection or interstitial fibrosis and tubular atrophy in protocol biopsy at 3 months in renal allograft recipients managed by preemptive therapy or antiviral prophylaxis.
    Reischig T, Jindra P, Hes O, Bouda M, Kormunda S, Treska V.
    Transplantation; 2009 Feb 15; 87(3):436-44. PubMed ID: 19202451
    [Abstract] [Full Text] [Related]

  • 5. Cytomegalovirus serostatus pairing and deceased donor kidney transplant outcomes in adult recipients with antiviral prophylaxis.
    Kuo HT, Ye X, Sampaio MS, Reddy P, Bunnapradist S.
    Transplantation; 2010 Nov 27; 90(10):1091-8. PubMed ID: 20885340
    [Abstract] [Full Text] [Related]

  • 6. Analysis of the QuantiFERON-CMV assay, CMV viraemia and antiviral treatment following solid organ transplantation in Western Australia.
    Thompson G, Boan P, Baumwol J, Chakera A, MacQuillan G, Swaminathan S, Lavender M, Flexman J, James I, John M.
    Pathology; 2018 Aug 27; 50(5):554-561. PubMed ID: 29945729
    [Abstract] [Full Text] [Related]

  • 7. Effect of Preemptive Therapy vs Antiviral Prophylaxis on Cytomegalovirus Disease in Seronegative Liver Transplant Recipients With Seropositive Donors: A Randomized Clinical Trial.
    Singh N, Winston DJ, Razonable RR, Lyon GM, Silveira FP, Wagener MM, Stevens-Ayers T, Edmison B, Boeckh M, Limaye AP.
    JAMA; 2020 Apr 14; 323(14):1378-1387. PubMed ID: 32286644
    [Abstract] [Full Text] [Related]

  • 8. Cytomegalovirus infection in living-donor and cadaveric lung transplantations.
    Ohata K, Chen-Yoshikawa TF, Takahashi K, Aoyama A, Motoyama H, Hijiya K, Hamaji M, Menju T, Sato T, Sonobe M, Takakura S, Date H.
    Interact Cardiovasc Thorac Surg; 2017 Nov 01; 25(5):710-715. PubMed ID: 29049752
    [Abstract] [Full Text] [Related]

  • 9. Diagnostic utility of monitoring cytomegalovirus-specific immunity by QuantiFERON-cytomegalovirus assay in kidney transplant recipients.
    Deborska-Materkowska D, Perkowska-Ptasinska A, Sadowska A, Gozdowska J, Ciszek M, Serwanska-Swietek M, Domagala P, Miszewska-Szyszkowska D, Sitarek E, Jozwik A, Kwiatkowski A, Durlik M.
    BMC Infect Dis; 2018 Apr 16; 18(1):179. PubMed ID: 29661141
    [Abstract] [Full Text] [Related]

  • 10. Cytomegalovirus infection: its incidence and management in cytomegalovirus-seropositive living related liver transplant recipients: a single-center experience.
    Wadhawan M, Gupta S, Goyal N, Vasudevan KR, Makki K, Dawar R, Sardana R, Lal N, Kumar A.
    Liver Transpl; 2012 Dec 16; 18(12):1448-55. PubMed ID: 22903934
    [Abstract] [Full Text] [Related]

  • 11. Incidence of Cytomegalovirus DNAemia in Pediatric Kidney Transplant Recipients After Cessation of Antiviral Prophylaxis.
    Chaiyapak T, Borges K, Williams A, Banh T, Vasilevska-Ristovska J, Allen U, Parekh RS, Hébert D.
    Transplantation; 2018 Aug 16; 102(8):1391-1396. PubMed ID: 29377877
    [Abstract] [Full Text] [Related]

  • 12. [Monitoring of cytomegalovirus-specific CD4+ and CD8+ T cell responses by cytokine flow cytometry in renal transplant recipients].
    Kılınçkaya Doğan H, Mutlu E, Köksoy S, Yılmaz VT, Koçak H, Çolak D, Mutlu D, Günseren F, Dinçkan A, Aliosmanoğlu İ, Süleymanlar G, Gültekin M.
    Mikrobiyol Bul; 2016 Apr 16; 50(2):224-35. PubMed ID: 27175495
    [Abstract] [Full Text] [Related]

  • 13. Cytomegalovirus prophylaxis in seropositive renal transplant recipients receiving thymoglobulin induction therapy: Outcome and risk factors for late CMV disease.
    Reusing JO, Feitosa EB, Agena F, Pierrotti LC, Azevedo LSF, Kotton CN, David-Neto E.
    Transpl Infect Dis; 2018 Oct 16; 20(5):e12929. PubMed ID: 29809309
    [Abstract] [Full Text] [Related]

  • 14. Intragraft cytomegalovirus infection: a randomized trial of valacyclovir prophylaxis versus pre-emptive therapy in renal transplant recipients.
    Reischig T, Nemcová J, Vanecek T, Jindra P, Hes O, Bouda M, Treska V.
    Antivir Ther; 2010 Oct 16; 15(1):23-30. PubMed ID: 20167988
    [Abstract] [Full Text] [Related]

  • 15. Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial.
    Witzke O, Hauser IA, Bartels M, Wolf G, Wolters H, Nitschke M, VIPP Study Group.
    Transplantation; 2012 Jan 15; 93(1):61-8. PubMed ID: 22094954
    [Abstract] [Full Text] [Related]

  • 16. Cytomegalovirus viremia in lung transplant recipients receiving ganciclovir and immune globulin.
    Gutiérrez CA, Chaparro C, Krajden M, Winton T, Kesten S.
    Chest; 1998 Apr 15; 113(4):924-32. PubMed ID: 9554627
    [Abstract] [Full Text] [Related]

  • 17. Cytomegalovirus (CMV) prophylaxis by acyclovir in pre-transplant CMV-positive renal transplant recipients.
    Rostaing L, Crespin A, Icart J, Lloveras JJ, Durand D, Martinet O, Didier J.
    Transpl Int; 1994 Apr 15; 7 Suppl 1():S331-5. PubMed ID: 11271244
    [Abstract] [Full Text] [Related]

  • 18. Everolimus-based immunosuppressive regimens in lung transplant recipients: impact on CMV infection.
    Rittà M, Costa C, Solidoro P, Sidoti F, Libertucci D, Boffini M, Rinaldi M, Baldi S, Cavallo R.
    Antiviral Res; 2015 Jan 15; 113():19-26. PubMed ID: 25446337
    [Abstract] [Full Text] [Related]

  • 19. Impact of Prophylaxis vs Pre-emptive Approach for Cytomegalovirus Infection in Kidney Transplant Recipients.
    Kır O, Zeytinoğlu A, Arda B, Yılmaz M, Aşçı G, Töz H.
    Transplant Proc; 2017 Apr 15; 49(3):537-540. PubMed ID: 28340829
    [Abstract] [Full Text] [Related]

  • 20. Pre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipients.
    Owers DS, Webster AC, Strippoli GF, Kable K, Hodson EM.
    Cochrane Database Syst Rev; 2013 Feb 28; 2013(2):CD005133. PubMed ID: 23450558
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 46.